Developing Covid-19 Vaccines at Pandemic Speed
Abstract
Developing Covid-19 Vaccines at Pandemic Speed An ideal vaccine platform would support development from viral sequencing to clinical trials in less than 16 weeks, demonstrate elicitation of consist...
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Prior to this study, three candidate vaccines against SARS-CoV-2 were reported: ChAdOx1 nCoV-19, a DNA vaccine, and PiCoVacc.
“Prior to our reporting of this BBIBP-CorV study, three candidate vaccines against SARS-CoV-2 were reported, including an adenovirus-vectored vaccine (ChAdOx1 nCoV-19), a DNA vaccine, and an inactivated vaccine (PiCoVacc) (Gao et al., 2020, Lurie et al., 2020, van Doremalen et al., 2020, Yu et al., 2020a).”
From Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 (2020) · cites this paper as Lurie et al., 2020
Previous reports on SARS and MERS vaccine candidates raised concerns about pulmonary immunopathology caused by Th2 response or ADE.
“Previous reports on the development of SARS and MERS vaccine candidates raised concerns about pulmonary immunopathology, either directly caused by a type 2 helper T-cell (Th2) response or as a result of ADE (4, 14, 15).”
From Development of an inactivated vaccine candidate for SARS-CoV-2 (2020) · cites this paper as [4]
The citation lists haven’t been fetched yet
References 2 · Cited by 1,557
- Authors
- Lurie, N., Saville, M., Hatchett, R., & Halton, J.
- Affiliations
- Coalition for Epidemic Preparedness Innovations (NO)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-21
- Volume
- 382
- Issue
- 21
- Pages
- 1969-1973
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013660050
- Cited by
- 1,557
- References
- 2
- Citations by year
- 2026: 25 · 2025: 45 · 2024: 83 · 2023: 180 · 2022: 276 · 2021: 490 · 2020: 457
- FWCI
- 46.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Legal, Health, Environmental and COVID-19 Challenges
- Keywords
- COVID-19 vaccines, vaccine development, vaccine platforms, viral genome sequencing, clinical trials, SARS-CoV-2
- MeSH terms
- Betacoronavirus, Drug Development, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Clinical Trials as Topic, Humans, Pneumonia, Viral, Time Factors, Vaccines, Synthetic, Viral Vaccines, Coronavirus Infections, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
